An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants

Addictive Behaviors

Volumn 31, Issue 9, 2006, Pages 1628-1649

  Ait Daoud, Nassima ^a   Malcolm Jr , Robert J ^b   Johnson, Bankole A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alcohol dependence; Alcohol withdrawal; Anticonvulsant; Carbamazepine; Glutamate; Humans; Opioid; Serotonin; Topiramate; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACAMPROSATE; AMINOTRANSFERASE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLOMETHIAZOLE; GABAPENTIN; GLUTAMATE RECEPTOR; LORAZEPAM; MU OPIATE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALTREXONE; NEUROSTEROID; ONDANSETRON; OPIATE RECEPTOR; OXAZEPAM; PHENOBARBITAL; RITANSERIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TIAPRIDE; TOPIRAMATE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; AGITATION; ALCOHOL WITHDRAWAL; ALCOHOLISM; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; BLOOD TOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; HUMAN; LANGUAGE DISABILITY; MEMORY DISORDER; NEUROTOXICITY; PARESTHESIA; PERCEPTION DISORDER; PSYCHOMOTOR RETARDATION; PSYCHOSIS; SIDE EFFECT; SPEECH DISORDER; WEIGHT REDUCTION;

ALCOHOL DETERRENTS; ALCOHOL-INDUCED DISORDERS; ALCOHOLISM; ANTICONVULSANTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID, MU; RESEARCH DESIGN; SEROTONIN ANTAGONISTS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33746500828     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2005.12.029     Document Type: Article

References (88)

1. Ait-Daoud, N. (2005). Relationship between 5-HT transporter function and craving among Hispanic patients with alcoholism. In M. Galanter (Chair), New pharmacologic approaches to alcoholism. Symposium conducted at the May 2005 meeting of the American Psychiatric Association and sponsored by the American Academy of Addiction Psychiatry, Atlanta, GA.
2. Alapati A. Side effect profile on two different starting doses of topiramate [abstract 2.233]. Epilepsia 40 Suppl. 7 (1999) 141-142
3. American Psychiatric Association. Substance-related disorders. Diagnostic and statistical manual of mental disorders, DSM-IV-TR. 4th ed., text revision (2000), American Psychiatric Association, Washington, DC 191-223
4. Anton R.F., Moak D.H., Waid L.R., Latham P.K., Malcolm R.J., and Dias J.K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. The American Journal of Psychiatry 156 (1999) 1758-1764
5. Anton R.F., Pettinati H., Zweben A., Kranzler H.R., Johnson B., Bohn M.J., et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. Journal of Clinical Psychopharmacology 24 (2004) 421-428
6. Anton R.F., and Swift R.M. Current pharmacotherapies of alcoholism: A U.S. perspective. The American Journal on Addictions 12 Suppl. 1 (2003) S53-S68
7. Bailey C.P., Molleman A., and Little H.J. Comparison of the effects of drugs on hyperexcitability induced in hippocampal slices by withdrawal from chronic ethanol consumption. British Journal of Pharmacology 123 (1998) 215-222
8. Bocci U., and Beretta G. Experience with sodium dipropylacetate in alcoholics and cases of drug addiction. Lavoro Neuropsichiatrico 58 (1976) 51-56
9. Bonnet U., Banger M., Leweke F.M., Maschke M., Kowalski T., and Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry 32 (1999) 107-109
10. Bonnet U., Banger M., Leweke F.M., Specka M., Muller B.W., Hashemi T., et al. Treatment of acute alcohol withdrawal with gabapentin: Results from a controlled two-center trial. Journal of Clinical Psychopharmacology 23 (2003) 514-519
11. Bozikas V., Petrikis P., Gamvrula K., Savvidou I., and Karavatos A. Treatment of alcohol withdrawal with gabapentin. Progress in Neuro-Psychopharmacology & Biological Psychiatry 26 (2002) 197-199
12. Brady K.T., Myrick H., Henderson S., and Coffey S.F. The use of divalproex in alcohol relapse prevention: A pilot study. Drug and Alcohol Dependence 67 (2002) 323-330
13. Brausseur R. Depakene in the treatment of chronic alcoholism. Therapiewoche 28 (1978) 9981-9984
14. Chatterjee C.R., and Ringold A.L. A case report of reduction in alcohol craving and protection against alcohol withdrawal by gabapentin. Journal of Clinical Psychiatry 60 (1999) 617
15. Chick J., Anton R., Checinski K., Croop R., Drummond D.C., Farmer R., et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol and Alcoholism 35 (2000) 587-593
16. Choi E.A., Ki S.W., Kim S.E., Kim J.W., and Park J.K. The efficacy and safety of topiramate in the treatment of alcohol withdrawal. Journal of the Korean Neuropsychiatric Association 44 (2005) 328-333
17. Food and Drug Administration. CAMPRAL® (acamprosate calcium) delayed-release tablets [approved label] (2004). http://www.fda.gov/cder/foi/label/2004/21431lbl.pdf Retrieved November 7, 2005, from http://www.fda.gov/cder/foi/label/2004/21431lbl.pdf
18. Garbutt J.C., West S.L., Carey T.S., Lohr K.N., and Crews F.T. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA, The Journal of the American Medical Association 281 (1999) 1318-1325
19. Garnett W.R. Clinical pharmacology of topiramate: A review. Epilepsia 41 Suppl. 1 (2000) S61-S65
20. Gastpar M., Bonnet U., Boning J., Mann K., Schmidt L.G., Soyka M., et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse: Results from a German multicenter study. Journal of Clinical Psychopharmacology 22 (2002) 592-598
21. Geerlings P.J., Ansoms C., and van den Brink W. Acamprosate and prevention of relapse in alcoholics: Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in the Netherlands, Belgium and Luxembourg. European Addiction Research 3 (1997) 129-137
22. Gerra G., Caccavari R., Delsignore R., Bocchi R., Fertonani G., and Passeri M. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Current Therapeutic Research 52 (1992) 291-295
23. Hammer B.A., and Brady K.T. Valproate treatment of alcohol withdrawal and mania. The American Journal of Psychiatry 153 (1996) 1232
24. Heinala P., Alho H., Kiianmaa K., Lonnqvist J., Kuoppasalmi K., and Sinclair J.D. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 21 (2001) 287-292
25. Herrero A.I., Del Olmo N., Gonzalez-Escalada J.R., and Solis J.M. Two new actions of topiramate: Inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology 42 (2002) 210-220
26. Hillbom M., Tokola R., Kuusela V., Karkkainen P., Kalli-Lemma L., Pilke A., et al. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol 6 (1989) 223-226
27. Johnson B.A. Progress in the development of topiramate for treating alcohol dependence: From a hypothesis to a proof-of-concept study. Alcoholism, Clinical and Experimental Research 28 (2004) 1137-1144
28. Johnson B.A. Recent advances in the development of treatments for alcohol and cocaine dependence: Focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs 19 (2005) 873-896
29. Johnson B.A., and Ait-Daoud N. Neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Psychopharmacology 149 (2000) 327-344
30. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet 361 (2003) 1677-1685
31. Johnson B.A., Campling G.M., Griffiths P., and Cowen P.J. Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: A preliminary study in healthy male volunteers. Psychopharmacology 112 (1993) 142-144
32. Johnson B.A., Jasinski D.R., Galloway G.P., Kranzler H., Weinreib R., Anton R.F., et al. Ritanserin in the treatment of alcohol dependence-A multi-center clinical trial. Ritanserin Study Group. Psychopharmacology 128 (1996) 206-215
33. Johnson B.A., Mann K., Willenbring M.L., Litten R.Z., Swift R.M., Lesch O.M., et al. Challenges and opportunities for medications development in alcoholism: An international perspective on collaborations between academia and industry. Alcoholism, Clinical and Experimental Research 29 (2005) 1528-1540
34. Johnson B.A., Roache J.D., Javors M.A., DiClemente C.C., Cloninger C.R., Prihoda T.J., et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA, The Journal of the American Medical Association 284 (2000) 963-971
35. Karam-Hage M., and Brower K.J. Gabapentin treatment for insomnia associated with alcohol dependence. The American Journal of Psychiatry 157 (2000) 151
36. Knapp D.J., Overstreet D.H., and Breese G.R. Modulation of ethanol withdrawal-induced anxiety-like behavior during later withdrawals by treatment of early withdrawals with benzodiazepine/gamma-aminobutyric acid ligands. Alcoholism, Clinical and Experimental Research 29 (2005) 553-563
37. Kranzler H.R., Bauer L.O., Hersh D., and Klinghoffer V. Carbamazepine treatment of cocaine dependence: A placebo-controlled trial. Drug and Alcohol Dependence 38 (1995) 203-211
38. Kranzler H.R., Modesto-Lowe V., and Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence: A placebo-controlled trial. Neuropsychopharmacology 22 (2000) 493-503
39. Kranzler H.R., Pierucci-Lagha A., Feinn R., and Hernandez-Avila C. Effects of ondansetron in early- versus late-onset alcoholics: A prospective, open-label study. Alcoholism, Clinical and Experimental Research 27 (2003) 1150-1155
40. Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., Rosenheck R.A., and Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine 345 (2001) 1734-1739
41. Ladewig D., Knecht T., Leher P., and Fendl A. Acamprosate: A stabilizing factor in long-term withdrawal of alcoholic patients. Therapeutische Umschau 50 (1993) 182-188
42. Lambie D.G., Johnson R.H., Vijayasenan M.E., and Whiteside E.A. Sodium valproate in the treatment of the alcohol withdrawal syndrome. Australian and New Zealand Journal of Psychiatry 14 (1980) 213-215
43. Latt N.C., Jurd S., Houseman J., and Wutzke S.E. Naltrexone in alcohol dependence: A randomised controlled trial of effectiveness in a standard clinical setting. The Medical Journal of Australia 176 (2002) 530-534
44. A receptors in the ventral tegmental area. Nature Neuroscience 7 (2004) 160-169
45. Lesch O.M., Riegler A., Gutierrez K., Hertling I., Ramskogler K., Semler B., et al. The European acamprosate trials: Conclusions for research and therapy. Journal of Biomedical Science 8 (2001) 89-95
46. Litten R.Z., and Allen J.P. Advances in development of medications for alcoholism treatment. Psychopharmacology 139 (1998) 20-33
47. Littleton J.M., De Witte P., Litten R., Gessa G.L., Spanagel R., Kranzler H., et al. Challenges to medications development in treating alcohol dependence: An international perspective. Summary of a symposium held at the ESBRA Congress, Prague, 13 September 2003. Alcohol and Alcoholism 39 (2004) 271-275
48. Longo L.P., Campbell T., and Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. Journal of Addictive Diseases 21 (2002) 55-64
49. Malcolm R.J. GABA systems, benzodiazepines, and substance dependence. Journal of Clinical Psychiatry 64 Suppl. 3 (2003) 36-40
50. Malcolm R., Myrick H., Brady K.T., and Ballenger J.C. Update on anticonvulsants for the treatment of alcohol withdrawal. The American Journal on Addictions 10 Suppl. (2001) 16-23
51. Malcolm R., Myrick H., Roberts J., Wang W., and Anton R.F. The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification. The American Journal on Addictions 11 (2002) 141-150
52. Malcolm R., Myrick H., Roberts J., Wang W., Anton R.F., and Ballenger J.C. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. Journal of General Internal Medicine 17 (2002) 349-355
53. Mann K. Pharmacotherapy of alcohol dependence: A review of the clinical data. CNS Drugs 18 (2004) 485-504
54. Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., and Cutler R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Archives of General Psychiatry 56 (1999) 719-724
55. McLean M.J. Gabapentin in the management of convulsive disorders. Epilepsia 40 Suppl. 6 (1999) S39-S50
56. Monterosso J.R., Flannery B.A., Pettinati H.M., Oslin D.W., Rukstalis M., O'Brien C.P., et al. Predicting treatment response to naltrexone: The influence of craving and family history. The American Journal on Addictions 10 (2001) 258-268
57. Monti P.M., Rohsenow D.J., Swift R.M., Gulliver S.B., Colby S.M., Mueller T.I., et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcoholism, Clinical and Experimental Research 25 (2001) 1634-1647
58. Morris P.L., Hopwood M., Whelan G., Gardiner J., and Drummond E. Naltrexone for alcohol dependence: A randomized controlled trial. Addiction 96 (2001) 1565-1573
59. Mueller T.I., Stout R.L., Rudden S., Brown R.A., Gordon A., Solomon D.A., et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcoholism, Clinical and Experimental Research 21 (1997) 86-92
60. Myrick H., Brady K.T., and Malcolm R. Divalproex in the treatment of alcohol withdrawal. American Journal of Drug and Alcohol Abuse 26 (2000) 155-160
61. Myrick H., Malcolm R., and Brady K.T. Gabapentin treatment of alcohol withdrawal. The American Journal of Psychiatry 155 (1998) 1632
62. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., and Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry 49 (1992) 881-887
63. Ortho-McNeil Pharmaceutical, Inc. Topamax® [package insert] (2003), Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ
64. Oslin D., Liberto J.G., O'Brien J., Krois S., and Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. The American Journal of Geriatric Psychiatry 5 (1997) 324-332
65. Paille F.M., Guelfi J.D., Perkins A.C., Royer R.J., Steru L., and Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol and Alcoholism 30 (1995) 239-247
66. Pelc I., Verbanck P., Le Bon O., Gavrilovic M., Lion K., and Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. British Journal of Psychiatry 171 (1997) 73-77
67. Petroff O.A., Hyder F., Rothman D.L., and Mattson R.H. Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia 41 (2000) 675-680
68. Pettinati H.M., Volpicelli J.R., Kranzler H.R., Luck G., Rukstalis M.R., and Cnaan A. Sertraline treatment for alcohol dependence: Interactive effects of medication and alcoholic subtype. Alcoholism, Clinical and Experimental Research 24 (2000) 1041-1049
69. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92 (1997) 1537-1546
70. Polycarpou A., Papanikolaou P., Ioannidis J., and Contopoulos-Ioannidis D. Anticonvulsants for alcohol withdrawal. Cochrane Database of Systematic Reviews 3 (2005) CD005064
71. Reoux J.P., Saxon A.J., Malte C.A., Baer J.S., and Sloan K.L. Divalproex sodium in alcohol withdrawal: A randomized double-blind placebo-controlled clinical trial. Alcoholism, Clinical and Experimental Research 25 (2001) 1324-1329
72. Rosenthal R.N., Perkel C., Singh P., Anand O., and Miner C.R. A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. The American Journal on Addictions 7 (1998) 189-197
73. Roussaux J.P., Hers D., and Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics?. Journal de Pharmacie de Belgique 51 (1996) 65-68
74. Rustembegovic A., Sofic E., and Kroyer G. A pilot study of topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Medicinski Arhiv 56 (2002) 211-212
75. Rustembegovic A., Sofic E., Tahirovic I., and Kundurovic Z. A study of gabapentin in the treatment of tonic-clonic seizures of alcohol withdrawal syndrome. Medicinski Arhiv 58 (2004) 5-6
76. Salloum I.M., Cornelius J.R., Daley D.C., Kirisci L., Himmelhoch J.M., and Thase M.E. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: A double-blind placebo-controlled study. Archives of General Psychiatry 62 (2005) 37-45
77. Sarup A., Larsson O.M., and Schousboe A. GABA transporters and GABA-transaminase as drug targets. Current Drug Targets. CNS and Neurological Disorders 2 (2003) 269-277
78. Sass H., Soyka M., Mann K., and Zieglgansberger W. Relapse prevention by acamprosate: Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry 53 (1996) 673-680 [Erratum appears in Archives of General Psychiatry, 53, 1097 (1996)]
79. Shank R.P., Gardocki J.F., Streeter A.J., and Maryanoff B.E. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41 Suppl. 1 (2000) S3-S9
80. Spanagel R., and Zieglgansberger W. Anti-craving compounds for ethanol: New pharmacological tools to study addictive processes. Trends in Pharmacological Sciences 18 (1997) 54-59
81. Sullivan J.T., Sykora K., Schneiderman J., Naranjo C.A., and Sellers E.M. Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). British Journal of Addiction 84 (1989) 1353-1357
82. Swift R.M., Davidson D., Whelihan W., and Kuznetsov O. Ondansetron alters human alcohol intoxication. Biological Psychiatry 40 (1996) 514-521
83. Volpicelli J.R., Alterman A.I., Hayashida M., and O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 49 (1992) 876-880
84. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., and O'Brien C.P. Naltrexone and alcohol dependence: Role of subject compliance. Archives of General Psychiatry 54 (1997) 737-742
85. Voris J., Smith N.L., Rao S.M., Thorne D.L., and Flowers Q.J. Gabapentin for the treatment of ethanol withdrawal. Substance Abuse 24 (2003) 129-132
86. Watson W.P., Robinson E., and Little H.J. The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharmacology 36 (1997) 1369-1375
87. Whitworth A.B., Fischer F., Lesch O.M., Nimmerrichter A., Oberbauer H., Platz T., et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347 (1996) 1438-1442
88. Wiesbeck G.A., Weijers H.G., Chick J., Naranjo C.A., and Boening J. Ritanserin in relapse prevention in abstinent alcoholics: Results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcoholism, Clinical and Experimental Research 23 (1999) 230-235